TRUPCR® DPYD Testing Kit (now available with Interpretation Software)

The CE-IVDTRUPCR® DPYD Testing Kitis an in vitro diagnostic test intended for the detection of clinically relevant single nucleotide polymorphisms (SNPs) ; c.1905+1G>A (rs3918290, also IVS14+1G>A, allele 2A*), c.1679T>G (rs55886062, allele 13*), c.2846A>T (rs67376798) and c.1129–5923C>G (rs75017182, HapB3) in dihydropyrimidine dehydrogenase (DPD) enzyme encoding gene DPYD from human genomic DNA, extracted from blood/bone marrow. The DPYD Flyer can be downloaded here Fluoropyrimidines such as 5-fluorouracil (5-FU), capecitabine and tegafur are commonly used drugs for treating solid tumours. These drugs are metabolized in the liver by enzyme dihydropyrimidine dehydrogenase (DPD) which inactivates more than 80% of these drugs. Certain single point mutations in the gene encoding this enzyme, DPYD can result in no/reduced activity of the enzyme leading to toxicity. Spectrum of severity of toxicity varies wherein patients with decreased DPD activity may experience diarrhoea, nausea, vomiting, may require hospitalization and dose reduction, patients with complete lack of DPD activity may experience life-threatening toxicity and need to be removed from the therapy. A more detailed overview of DPYD testing can be found here The TRUPCR®DPYD Testing Kitis based on allele-specific amplification and is achieved by ARMS PCR. The detection of the SNPs is achieved in multiplex reactions using fluorescent probes labelled with FAM/HEX or TEXAS RED where FAM/HEX inform about the SNP of interest, TEXAS RED acts as an internal reference. The internal reference is the part of the DPYD gene with no known mutation. The RUO TRUPCR interpretation software simplifies and accelerate results analysis: